HOME >> BIOLOGY >> NEWS
Other highlights in the February 18 issue of JNCI

Two Studies Examine Aspirin for Cancer Prevention

Two studies in the February 18 issue of JNCI address the association between aspirin use and the risk of two different types of cancer.

In one study, Ellen T. Chang, Sc.D., of the Harvard School of Public Health, and colleagues examined the association between various pain relievers and the risk of Hodgkin's lymphoma. In a case-control study, participants were asked to report their average use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) and of acetaminophen over the previous 5 years. They found that the risk of Hodgkin's lymphoma was lower with regular aspirin use (2 or more tablets per week) than with non-regular aspirin use, and that there was no association between risk of Hodgkin's lymphoma and use of other non-aspirin NSAIDs, but the risk was higher with regular acetaminophen use.

"If aspirin use is indeed found to protect against Hodgkin's lymphoma, this relationship could afford insight into the pathogenesis of the disease and offer possible clues toward its prevention," the authors write.

In a second study, Chin Hur, M.D., of Massachusetts General Hospital, and colleagues examined the cost-effectiveness of aspirin as a chemoprevention strategy for esophageal cancer in patients with Barrett's esophagus. Patients with Barrett's esophagus are at an increased risk for esophageal cancer and, as such, often undergo periodic endoscopic screening. Aspirin use has been associated with a reduced risk of esophageal cancer, but the use of aspirin can cause bleeding and other harms.

Using a model analysis to compare the effectiveness and cost-effectiveness of aspirin for the chemoprevention of esophageal cancer in patients with Barrett's esophagus, Hur and colleagues found that aspirin therapy with or without endoscopic surveillance was both more effective (in terms of quality-adjusted life years) and cost less than no therapy or just endoscopic
'"/>

Contact: Katherine Arnold
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
17-Feb-2004


Page: 1 2 3

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 19 JNCI
8. Other highlights in the May 5 JNCI
9. Other highlights of the March 17 issue of JNCI
10. Other highlights in the March 3 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/15/2018)... ... September 14, 2018 , ... Today, Mediaplanet announces the ... innovative work being done within rare diseases research, diagnostics, and will highlight what ... rare diseases. , The print component of "Rare Diseases" is ...
(Date:9/12/2018)... Minn. (PRWEB) , ... September 11, 2018 , ... ... wall coatings, is proud to introduce the new ChemXP™ line of high performance ... environments. The line was developed to provide Tennant Coatings’ elite certified installers with ...
(Date:9/12/2018)... ... 12, 2018 , ... Captiva Spine, Inc., which designs, manufactures ... 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market TowerLOX-EXT® ... TowerLOX-EXT MIS Extended Tab Pedicle Screws provide the narrow insertion of an extended ...
Breaking Biology News(10 mins):
(Date:9/7/2018)... ... September 06, 2018 , ... The Discovery on ... meeting of “The industry’s preeminent event on novel drug targets.” BellBrook Labs’ high ... to study these emerging targets in a quest to find new treatments for ...
(Date:8/31/2018)... ... 2018 , ... A recent expedition led by Dr. Blair ... of Industrial Science, the University of Tokyo, demonstrated how the use of autonomous ... of hard to reach deep sea ecosystems, like intermittently active methane seeps. Thanks ...
(Date:8/29/2018)... ... 2018 , ... CEO and founder of VetStem Biopharma, Dr. ... an allogeneic (donor derived) stem cell product for osteoarthritis in canines at the ... He is also the organizer of Breakout Session 4: Practitioner Primer on FDA ...
(Date:8/23/2018)... RENO/TAHOE, Nev. (PRWEB) , ... August 22, 2018 ... ... TrialKit ™ for Android on September 1st, making it the first fully-featured ... both iOS and Android devices. Combined, iOS and Android constitute 99 percent of ...
Breaking Biology Technology:
Cached News: